A Phase 2, Open-label, Multicenter Study to Determine the Safety, Tolerability, and Efficacy of MK- 1045 in Participants with Hematologic Malignancies
This study is testing a new medicine called MK-1045 in adults living with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). Both are types of slow-growing blood cancers that affect white blood cells. The main aim of the trial is to find out if MK-1045 is safe to use and how well the body handles it. Doctors will check for side effects and see if the treatment helps shrink the cancer or stop it from growing. Another medicine called tocilizumab may also be used to help manage specific immune-related side effects if they happen. Because this is an open-label trial, both you and your medical team will know that you are receiving the study medicine. The results will help researchers decide if MK-1045 could become a helpful future treatment option.
At a glance
What is this study about?
Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) are closely related types of blood cancer. They affect white blood cells called lymphocytes, which are an important part of your immune system. While there are treatments currently available, these conditions can return or stop responding to standard therapies. Because of this, researchers are constantly searching for new, more effective options.
This trial is testing a new investigational drug called MK-1045. The study is in 'Phase 2', which means the drug has already been tested in a small number of people, and researchers now want to test it in a slightly larger group. They want to learn how safe it is, what side effects might occur, and whether it effectively slows down or shrinks the cancer.
During the trial, doctors will also have another medicine ready, called tocilizumab. This is a medicine commonly used to calm the immune system if it reacts too strongly to treatment. By watching participants closely, the trial team aims to understand the best and safest ways to give MK-1045 in the future.
This study is 'open-label', meaning no one receives a dummy drug (placebo). Both you and your hospital team will know exactly what medicine you are taking at every stage of the study.
Key takeaways
- Phase 2 clinical trial testing a new drug called MK-1045 for CLL and SLL.
- Aims to check the safety, side effects, and cancer-fighting ability of the medicine.
- Open to adults aged 18 and older who meet specific health checks.
- Everyone on the trial receives the active study treatment; there is no placebo.
- Participation is entirely voluntary and you can stop at any time.
Who may be eligible?
This trial is open to adults aged 18 and over who have been diagnosed with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). Men and women can both take part.
To join, participants usually need to have reached a point where their condition requires treatment, or where previous treatments are no longer working well. Your overall health and organ function (such as how well your kidneys and liver are working) will also be checked to make sure it is safe for you to take part.
You may not be able to join if you have certain other serious medical conditions, active severe infections, or if you are pregnant or breastfeeding. Your hospital doctor or the study team will carry out tests to confirm whether this trial is suitable for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
- My cancer requires treatment or has stopped responding to other therapies.
- I am well enough to attend regular hospital appointments for tests and treatment.
- I am willing to discuss my full medical history and current medications with the trial team.
What does participation involve?
Taking part involves attending a specialist hospital or clinical trial centre. Before starting, you will have health checks, including physical exams, blood tests, and scans, to confirm you are safe to join. During the trial, you will receive the study medicine, MK-1045, and the medical team will watch you closely for any side effects. You will have regular blood tests to check how the drug travels through your body and whether your immune system makes any antibodies against it. If you develop certain strong immune reactions, you may also receive a medicine called tocilizumab to help settle them. The overall length of your participation will depend on how well your body tolerates the drug and whether the treatment is helping your cancer, followed by a period of routine health check-ins.
Potential risks and benefits
Locations (2)
- —UnverifiedSpain
- —UnverifiedItaly
Common questions
What is an open-label study?
An open-label study means that both you and your doctor know which medicine you are receiving. There is no fake treatment or dummy drug (placebo) used in this trial.
What is the difference between CLL and SLL?
They are essentially the same disease, but CLL is found mostly in the blood and bone marrow, whereas SLL is found mainly in the lymph nodes.
Why might I be given tocilizumab?
Tocilizumab is a medicine that helps calm the immune system. It is kept on hand in case your body has a strong immune reaction to the main study drug.
Do I have to pay to take part in this trial?
No, clinical trials in the UK do not charge participants for the study medicines or trial-related tests. Some trials may also help cover travel expenses.
Can I leave the trial if I change my mind?
Yes, you can leave the study at any point. Deciding to withdraw will never affect your relationship with your healthcare team or your normal medical treatment.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.